Functional outcome and complications after treatment of comminuted tibial fractures or deformities using Ilizarov bone transport: a single-center study at 15- to 30-year follow-up

Introduction - The aim of this retrospective study was to evaluate long-term outcomes and complications of a single-center and single-surgeon patient series of isolated and comminuted tibial fractures with bone defects or tibial deformities treated by Ilizarov bone transport. Materials and methods - Data from a consecutive series of patients with isolated comminuted tibial fractures (Fracture Group: FG) or deformities (Deformity Group: DG) treated between 1987 and 2002 were included. For clinical assessment, the Lower Extremities Functional Scale was used; complications were recorded according to the Dindo classification and statistical analysis was performed. Results - Overall, 72 patients were enrolled with a mean follow-up of 21.6 years (range 15\u201330) a mean LEFS of 36.4 (range 0\u2013100). In the FG, the mean LEFS was 21.3 (range 0\u201398.75), and the external fixation time (EFT) lasted 7.6 months (range 3\u201318 months) months. In the DG, the mean LEFS was 76.7 (range 55\u2013100), and the EFT was 10.6 months (range 3\u201320 months). Between the two groups, the clinical evaluation was significantly different, while the EFT was not (p = 0.14). In the FG, the worst results were obtained in the cases of open fractures with a higher percentage of complications and the need for further surgical procedures. The cumulative rate of complications was 55.6% during the first 36 months and 66.7% at the minimum follow-up of 180 months. Conclusions - Ilizarov bone transport, even at a long follow-up period, proved to be an effective technique for both definitive treatment of comminuted tibial fractures with bone defects or tibial deformities. Although our functional outcomes were lower in patients with exposed fractures, they were in line with the literature, but not influenced by the EFT when properly managed. Most complications occurred during the first 3 years; however, they could also arise much later, even until almost 30 years

Dataset of the manuscript “4D Imaging of the Volcano Feeding System beneath the Urban Area of the Campi Flegrei Caldera”

This work has been supported by Spanish Agencia Estatal de Investigación (10.13039/501100011033) grant RTI2018-093874-B-I00 (DEEP-MAPS), and grants G2HOTSPOTS (PID2021-122142OB-I00) and Defsour-PLUS (PDC2022-133304-I00) from the AEI/10.13039/501100011033/Union Europea NextGeneration. We thank ASI (Italian Space Agency) Project “DInSAR - 3M” (ASI Contract n. 2021-8-U.0 “DInSAR Multi-frequency/Multi-platform for Multi-scale analysis of ground movements” to partially support the activities. We also thank the Italian DPC and DInSAR-3M projects for partially funding this research activity and ASI and ESA for providing the SAR images. The efforts of KFT was supported in part by NOAA cooperative agreements NA17OAR4320101 and NA22OAR4320151 and NSF Award OAC 1835566. This work represents a contribution to CSIC PTI TELEDETEC.Peer reviewe

A geroscience approach for Parkinson's disease: Conceptual framework and design of PROPAG-AGEING project

Advanced age is the major risk factor for idiopathic Parkinson's disease (PD), but to date the biological relationship between PD and ageing remains elusive. Here we describe the rationale and the design of the H2020 funded project "PROPAG-AGEING", whose aim is to characterize the contribution of the ageing process to PD development. We summarize current evidences that support the existence of a continuum between ageing and PD and justify the use of a Geroscience approach to study PD. We focus in particular on the role of inflammaging, the chronic, low-grade inflammation characteristic of elderly physiology, which can propagate and transmit both locally and systemically. We then describe PROPAG-AGEING design, which is based on the multi-omic characterization of peripheral samples from clinically characterized drug-naive and advanced PD, PD discordant twins, healthy controls and "super-controls", i.e. centenarians, who never showed clinical signs of motor disability, and their offspring. Omic results are then validated in a large number of samples, including in vitro models of dopaminergic neurons and healthy siblings of PD patients, who are at higher risk of developing PD, with the final aim of identifying the molecular perturbations that can deviate the trajectories of healthy ageing towards PD development